Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials ; volume:11 ; number:6 ; day:25 ; month:9 ; year:2024 ; pages:1551-1567 ; date:12.2024
Rheumatology and therapy ; 11, Heft 6 (25.9.2024), 1551-1567, 12.2024
- Creator
-
Mease, Philip J.
Korotaeva, Tatiana
Shesternya, Pavel
Kokhan, Muza
Rukavitsyn, Anton
Vasilchenkov, Dmitry
Sharaf, Mohamed
Lavie, Frédéric
Deodhar, Atul
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-024-00713-x
- URN
-
urn:nbn:de:101:1-2501292143297.146914681894
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mease, Philip J.
- Korotaeva, Tatiana
- Shesternya, Pavel
- Kokhan, Muza
- Rukavitsyn, Anton
- Vasilchenkov, Dmitry
- Sharaf, Mohamed
- Lavie, Frédéric
- Deodhar, Atul
- SpringerLink (Online service)
Other Objects (12)
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis